Markush pharma patent claims supported by Beijing Higher People’s Court
A recent decision in China provides some assurance for pharmaceutical patent owners but the direction of Markush claims is still unclear
The Beijing Higher People’s Court in January
addressed the issue of whether partial priority should apply to
Markush claims. Markush claim is a claim with multiple
functionally equivalent chemical entities allowed in one or
more parts of the compound.
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.